Note 15 - Subsequent Events

12 Months Ended

Dec. 31, 2020

Notes to Financial Statements

Subsequent Events [Text Block]

15.

Subsequent Events

The Company has evaluated events subsequent to the balance sheet date for inclusion in the accompanying consolidated financial statements through the date of issuance and determined that

no

subsequent events have occurred that would require recognition in the consolidated financial statements or disclosures in the notes thereto.

Subsequent to

December 31, 2020,

the Company sold a total of

2,976,832

shares of common stock under the H.C. Wainwright ATM Agreement for aggregate gross proceeds of

$7,056,000

at an average selling price of

$2.37

per share, resulting in net proceeds of approximately

$6,832,000

after deducting commissions and other transaction costs of approximately

$224,000.

The Company has now completed the sale of all available amounts under the ATM Agreement.

In

March 2021,

ImmuneCyte entered into acquisition agreements with Boyalife Group to acquire the entire Boyalife Group's Cellular Therapy Division, in a stock transaction. Following the acquisition, the Company's investment in ImmuneCyte decreased from

18.79%

to approximately

8.8%.